Trinity Biotech (TRIB) Operating Leases (2020 - 2024)
Trinity Biotech (TRIB) has disclosed Operating Leases for 5 consecutive years, with $12.8 million as the latest value for Q4 2024.
- Quarterly Operating Leases rose 1.56% to $12.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Dec 2024, up 1.56% year-over-year, with the annual reading at $12.8 million for FY2024, 1.56% up from the prior year.
- Operating Leases hit $12.8 million in Q4 2024 for Trinity Biotech, up from $12.6 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $18.7 million in Q4 2020 to a low of $139000.0 in Q4 2021.
- Historically, Operating Leases has averaged $10.6 million across 5 years, with a median of $12.6 million in 2023.
- Biggest five-year swings in Operating Leases: crashed 99.26% in 2021 and later surged 6392.09% in 2022.
- Year by year, Operating Leases stood at $18.7 million in 2020, then plummeted by 99.26% to $139000.0 in 2021, then soared by 6392.09% to $9.0 million in 2022, then soared by 39.25% to $12.6 million in 2023, then grew by 1.56% to $12.8 million in 2024.
- Business Quant data shows Operating Leases for TRIB at $12.8 million in Q4 2024, $12.6 million in Q4 2023, and $9.0 million in Q4 2022.